



# Treating Patients With New-Onset Generalized Myasthenia Gravis?

Consider **referring** your patient to a clinical research study:

“A Phase 4, Open-Label, Prospective, Single-Group, Multicenter Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC\* in Adult Participants With New-Onset Generalized Myasthenia Gravis”

*\* The investigational study drug, efgartigimod PH20 SC, is approved by the FDA for use in generalized myasthenia gravis in adult patients who are acetylcholine receptor (AChR) antibody positive.*



or visit [www.clinicaltrials.gov](http://www.clinicaltrials.gov) (search for “NCT06909214”) for more information